Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy

Hepato-Gastroenterology

Volumn 53, Issue 68, 2006, Pages 171-174

  Wagatsuma, Yoshihisa ^a   Naritaka, Yoshihiko ^a   Shimakawa, Takeshi ^a   Kanako, Hamaguchi ^a   Keiichiro, Ishibashi ^a   Shunichi, Shiozaiva ^a   Konno, Soichi ^a   Katsube, Takao ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Losartan; Portal hemodynamics; Portal hypertensive gastropathy; Pulse Doppler ultrasonography

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; DOPPLER ECHOGRAPHY; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HEMODYNAMIC MONITORING; HUMAN; LIVER CIRRHOSIS; MALE; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; STOMACH DISEASE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD FLOW VELOCITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC MUCOSA; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LOSARTAN; MALE; MIDDLE AGED; PORTAL VEIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645562746     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Garcia Pagan JC, Bosh J, Rodes J, et al: The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 1995; 6:140-147.
2. Ballet F, Chretien Y, Rey C, Poupon R: Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988; 244:283-289.
3. Schneider AW, Kalk JF, Klein CP: Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29:334-339.
4. Toyonaga A, Iwao T: Portal hypertensive gastropathy. Jpn J Gastroenterol 1999; 96:619-626.
5. Moriyasu M, Nishida O, Ban N, et al: Measurement of "congestion index" of the portal vein by an ultrasonic duplex system. Jpn J Med Ultrasonics 1985; 12:138-145.
6. McCormack TT, Sims J, Eyre-Brook I, et al: Gastric lesions in portal hypertension; inflammatory gastritis or congestive gastropathy? Gut 1985; 26:1226-1232.
7. Sarin SK, Sreenivas DV, Lahoti D, et al: Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992; 102:994-999.
8. D'Amico G, Montalbano L, Triana M, et al: Natural history of congestive gastropathy in cirrhosis. Gastroenterology 1990; 99:1558-1564.
9. Hasumi A, Aoki H, Shimazu M, et al: Causative relationship between a hyperdynamic state due to increased A-V anastomoses in the gastric wall and AGML in patients with liver cirrhosis. J Gastroenterol Hepatol 1989; Suppl 1:143-145.
10. Okamoto K, Hasumi A, Fujita J, et al: A clinical study on the pathogenesis of portal hypertensive gastropathy. Jpn J Port Hypertens 2000; 6:1-6.
11. Quintero E, Pique JM, Bombi JA, et al: Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology 1987; 93:1054-1061.
12. Casadevall M, Panes J, Pique JM, et al: Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology 1993; 18:628-634.
13. Orloff MJ, Orloff MS, Orloff SL, et al: Treatment of bleeding from portal hypertensive gastropathy by portocaval shunt. Hepatology 1995; 21:1011-1017.
14. Urata J, Yamashita Y, Tsuchigame T, et al: The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998; 10:1061-1067.
15. Shigemori H, Iwao T, Ikegami M, et al: Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy. Dig Dis Sci 1994; 39:2433-2438.
16. Vallance P, Moncada S: Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776-778.
17. Rockey D: The cellular pathogenesis of portal hypertension: stellate cell contractility, endotherin, and nitric oxide. Hepatology 1997; 25:2-5.
18. Tieche S, De Gottardi A, Kappeler A, et al: Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 2001; 34:38-45.
19. Arroyo V, Bosch J, Mauri M, et al: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the rennin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11:221-229.
20. Bataller R, Gines P, Nicolas JM, et al: Angiotensin II induced contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118:1149-1156.
21. Ito M, Fujii M, Nakao S, et al: Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on portal blood flow in liver cirrhosis. Jpn J Port Hypertens 2001; 7:135-139.